Malaria vaccine.
Among infectious diseases caused by protozoa, malaria is still the greatest killer of children. Mortality in adults living in endemic areas is significantly lower because they frequently acquire partial or complete immunity to the major pathogen, Plasmodium falciparum. This natural protection indicates that vaccination may be possible, and the first candidate antigens were cloned with the use of human immune sera as probes. Genetic and biochemical analysis of the parasite proteins revealed that they are polymorphic, and frequently gene sequences were discovered which were specific for a particular parasite isolate, which eliminated most antigens for purposes of vaccine development. The most promising candidate antigens today are the major surface proteins of sporozoites and blood stage parasites. However, the immune response against those is not sufficient for complete protection, and additional, intensive research is necessary to identify new molecules to be included in a vaccine cocktail against malaria. The current spread of the disease due to increasing drug resistance of parasites and mosquito vectors emphasizes the urgent need for a vaccine.
Certa
U
U
Central Research Unit, Hoffmann-La Roche Ltd., Basel, Switzerland.
D000818:Animals; D000913:Antibodies, Protozoan / Q000276:immunology; D000953:Antigens, Protozoan / Q000276:immunology*; D006801:Humans; D007303:Insect Vectors; D008288:Malaria / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D010961:Plasmodium / Q000276:immunology*; D014611:Vaccination
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan